Caspase-independent pathways of programmed cell death: The unraveling of new targets of cancer therapy?
dc.contributor.author | Constantinou, Constantina | en |
dc.contributor.author | Papas, Konstantinos A. | en |
dc.contributor.author | Constantinou, Andreas I. | en |
dc.creator | Constantinou, Constantina | en |
dc.creator | Papas, Konstantinos A. | en |
dc.creator | Constantinou, Andreas I. | en |
dc.date.accessioned | 2019-11-04T12:50:25Z | |
dc.date.available | 2019-11-04T12:50:25Z | |
dc.date.issued | 2009 | |
dc.identifier.issn | 1568-0096 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/53012 | |
dc.description.abstract | In the past few years, accumulating evidence in the literature supports the existence of pathways of caspase-independent programmed cell death (CI-PCD). These pathways are likely to be acting as 'death backup systems' that ensure effective removal of defective cells from the organism. Similar to classical apoptosis i.e. caspase-dependent programmed cell death (CD-PCD), the mitochondrion is the main organelle orchestrating the series of events which are required for the induction of CI-PCD. In addition, the pro-apoptotic proteins Bax and Bid are also key participants in CI-PCD. However, contrary to CD-PCD, CI-PCD involves executioners other than the caspases which include the cathepsins, the calpains and serine proteases. The protein AIF may also play an important role in the induction of CI-PCD. In this review we report current knowledge on CI-PCD and provide evidence for its regulation by chemotherapeutic agents currently used in the clinic and under investigation in clinical trials. Lastly, we discuss how the study of natural and synthetic agents triggering CI-PCD may help in the pharmacological design of a new generation of more effective chemotherapeutic drugs. The use of such drugs activating both CD-PCD and CI-PCD pathways should achieve a more successful eradication of carcinogenic cells and the attainment of lower levels of tumor resistance. © 2009 Bentham Science Publishers Ltd. | en |
dc.source | Current Cancer Drug Targets | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349145859&doi=10.2174%2f156800909789271512&partnerID=40&md5=b51eb062535f3eb896bcbe9ea6cd7fac | |
dc.subject | antineoplastic agent | en |
dc.subject | Antineoplastic Agents | en |
dc.subject | human | en |
dc.subject | Humans | en |
dc.subject | breast cancer | en |
dc.subject | advanced cancer | en |
dc.subject | Chemotherapy | en |
dc.subject | clinical trial | en |
dc.subject | drug efficacy | en |
dc.subject | antineoplastic activity | en |
dc.subject | review | en |
dc.subject | lung non small cell cancer | en |
dc.subject | unindexed drug | en |
dc.subject | neoplasm | en |
dc.subject | solid tumor | en |
dc.subject | monoclonal antibody | en |
dc.subject | unclassified drug | en |
dc.subject | tumor cell | en |
dc.subject | prostate cancer | en |
dc.subject | liver cell carcinoma | en |
dc.subject | nonhuman | en |
dc.subject | oxidative stress | en |
dc.subject | signal transduction | en |
dc.subject | drug mechanism | en |
dc.subject | Apoptosis | en |
dc.subject | Clinical Trials as Topic | en |
dc.subject | gene expression | en |
dc.subject | drug targeting | en |
dc.subject | cell death | en |
dc.subject | cathepsin | en |
dc.subject | herbaceous agent | en |
dc.subject | Caspases | en |
dc.subject | regulatory mechanism | en |
dc.subject | leukemia | en |
dc.subject | Necrosis | en |
dc.subject | myeloma | en |
dc.subject | receptor upregulation | en |
dc.subject | Drug Delivery Systems | en |
dc.subject | carcinoid | en |
dc.subject | Models, Biological | en |
dc.subject | molecular interaction | en |
dc.subject | mediator | en |
dc.subject | drug design | en |
dc.subject | protein phosphorylation | en |
dc.subject | phenol derivative | en |
dc.subject | estradiol | en |
dc.subject | protein Bax | en |
dc.subject | cytotoxicity | en |
dc.subject | calpain | en |
dc.subject | flavone derivative | en |
dc.subject | apoptosis inducing factor | en |
dc.subject | Mitochondria | en |
dc.subject | mitochondrion | en |
dc.subject | caspase | en |
dc.subject | caspase inhibitor | en |
dc.subject | 2,4,6 triiodophenol | en |
dc.subject | 2' fluoro 6,7 methylenedioxy 2 phenyl 4 quinolone | en |
dc.subject | AIF | en |
dc.subject | AIF inhibitor | en |
dc.subject | apoptosis inhibitor | en |
dc.subject | Apoptosis Regulatory Proteins | en |
dc.subject | atiprimod | en |
dc.subject | azaspirane | en |
dc.subject | benzyloxycarbonylvalylalanylaspartyl fluoromethyl ketone | en |
dc.subject | bobel 24 | en |
dc.subject | bzl 101 | en |
dc.subject | carcinogenic activity | en |
dc.subject | Caspase-independent cell death | en |
dc.subject | cell organelle | en |
dc.subject | chm 1 | en |
dc.subject | chromatin condensation | en |
dc.subject | colecalciferol | en |
dc.subject | cy 103 | en |
dc.subject | Drug Discovery | en |
dc.subject | drug inhibition | en |
dc.subject | drug potency | en |
dc.subject | flavopiridol | en |
dc.subject | n methylpiperidinyl chlorophenyl flavone | en |
dc.subject | paclitaxel poliglumex | en |
dc.subject | Peptide Hydrolases | en |
dc.subject | Programmed cell death | en |
dc.subject | protein Bid | en |
dc.subject | protein induction | en |
dc.subject | quinolone derivative | en |
dc.subject | rb 110 | en |
dc.subject | rb 49 | en |
dc.subject | receptor down regulation | en |
dc.subject | serine proteinase | en |
dc.subject | tumor resistance | en |
dc.subject | vitamin D | en |
dc.title | Caspase-independent pathways of programmed cell death: The unraveling of new targets of cancer therapy? | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.2174/156800909789271512 | |
dc.description.volume | 9 | |
dc.description.startingpage | 717 | |
dc.description.endingpage | 728 | |
dc.author.faculty | Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences | |
dc.author.department | Τμήμα Βιολογικών Επιστημών / Department of Biological Sciences | |
dc.type.uhtype | Article | en |
dc.description.notes | <p>Tradenames: azaspirane | en |
dc.description.notes | bzl 101 | en |
dc.description.notes | chm 1 | en |
dc.description.notes | cy 103 | en |
dc.description.notes | rb 110 | en |
dc.description.notes | rb 49 | en |
dc.description.notes | xyotax | en |
dc.description.notes | Cited By :47</p> | en |
dc.source.abbreviation | Curr.Cancer Drug Targets | en |
dc.contributor.orcid | Constantinou, Andreas I. [0000-0003-0365-1821] | |
dc.gnosis.orcid | 0000-0003-0365-1821 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |